购物车
- 全部删除
- 您的购物车当前为空
PD-L1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.2 kDa and the accession number is Q9NZQ7-1.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
100 μg | ¥ 4,470 | 现货 | |
200 μg | ¥ 7,630 | 5日内发货 | |
500 μg | ¥ 15,450 | 5日内发货 |
生物活性 | Activity testing is in progress. It is theoretically active, but we cannot guarantee it. If you require protein activity, we recommend choosing the eukaryotic expression version first. |
产品描述 | PD-L1 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 25.2 kDa and the accession number is Q9NZQ7-1. |
种属 | Human |
表达系统 | HEK293 Cells |
标签 | Tag Free |
蛋白编号 | Q9NZQ7-1 |
别名 | PD-L1,PDL1,PDCD1LG1,PDCD1L1,CD274 molecule,B7-H1,B7H1,B7-H |
蛋白构建 | A DNA sequence encoding the human CD274 (NP_054862.1) (Met1-Arg238) was expressed. Predicted N terminal: Phe 19 |
蛋白纯度 | ≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC. |
分子量 | 25.2 kDa (predicted); 36 kDa (reducing condition, due to glycosylation) |
内毒素 | < 1.0 EU/μg of the protein as determined by the LAL method. |
缓冲液 | Lyophilized from a solution filtered through a 0.22 μm filter, containing PBS, pH 7.4. Typically, a mixture containing 5% to 8% trehalose, mannitol, and 0.01% Tween 80 is incorporated as a protective agent before lyophilization. |
复溶方法 | A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information. |
存储 | It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots. |
运输方式 | In general, Lyophilized powders are shipping with blue ice. |
研究背景 | Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain, and together with PD-L2, are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Blockade: Blocking AntibodiImmune Checkpoint Blockade: PD-L1 / B7-H1 / CImmune Checkpoint Detection: AntibodiesImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection: WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyPD-L1 / B7-H1 / CD274 Immune Checkpoint ProteTargeted Therapy |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.